Having trouble accessing articles? Reset your cache.

MetMAb: Preliminary Phase II data

Preliminary data from the double-blind, international Phase II OAM4558g trial in 128 patients showed that 15 mg/kg IV MetMAb every 3 weeks plus Tarceva erlotinib improved median

Read the full 270 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE